Enfermedades Infecciosas

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

Jiménez D, Martínez-Sanz J, Sainz T, Calvo C, Méndez-Echevarría A, Moreno E, Blázquez-Gamero D, Vizcarra P, Rodríguez M, Jenkins R, Sánchez-Conde M, Ron R, Norman F, Moreno S, Ferrer M, Serrano-Villar S.

Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.

JOURNAL OF INFECTION 2022. 85(1): 86-89.

[doi:10.1016/j.jinf.2022.04.041]
Escudero-Sanchez R, Muriel García A, García Fernández S, Valencia Alijo A, Tasias Pitarch M, Merino De Lucas E, Gutierrez Rojas A, Ramos Martínez A, Salavert Lletí M, Giner L, Ruíz Ruigomez M, García Basas L, Fernández Fradejas J, Olmedo Sampedrio M, Cano Yuste A, Díaz Pollán B, Rodríguez Hernández MJ, Martín Segarra O, Sáez Bejar C, Armiñanzas Castillo C, Gutiérrez B, Rodríguez-Pardo D, De La Torre Cisneros J, López Medrano F, Cobo Reinoso J.

Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2022. 77(7): 1996-2002. Nº de citas: 4

[doi:10.1093/jac/dkac106]
Serrano-Villar S, Moreno S.

Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.

Frontiers in immunology 2022. 13: 923905-923905.

[doi:10.3389/fimmu.2022.923905]
Serrano-Villar S, Wu K, Hunt PW, Lok JJ, Ron R, Sainz T, Moreno S, Deeks SG, Bosch RJ.

Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.

EBioMedicine 2022. 80: 104072-104072.

[doi:10.1016/j.ebiom.2022.104072]
Casado JL, Haemmerle J, Vizcarra P, Ramirez-Alonso G, Salazar-Tosco A, Romero-Hernandez B, Blasco M, Rodriguez-Dominguez M, Mirabella IG, Vallejo A, Fernandez-Escribano M.

Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination

Journal Of Clinical Medicine 2022. 11(12): . Nº de citas: 2

[doi:10.3390/jcm11123352]
Crespillo-Andújar C, Comeche B, Hamer DH, Arevalo-Rodriguez I, Alvarez-Díaz N, Zamora J, Pérez-Molina JA.

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.

PLOS NEGLECTED TROPICAL DISEASES 2022. 16(5): .

[doi:10.1371/journal.pntd.0010386]
Cortés A, Casado JL, Longo F, Serrano JJ, Saavedra C, Velasco H, Martin A, Chamorro J, Rosero D, Fernández M, Gion M, Martínez Jáñez N, Soria Rivas A, Alonso Gordoa T, Martínez Delfrade Í, Lage Y, López Miranda E, Olmedo ME, Reguera Puertas P, Gajate P, Molina Cerrillo J, Guerra Alia E, Fuentes Mateos R, Romero B, Rodríguez-Domínguez MJ, Vallejo A, Carrato A.

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

EUROPEAN JOURNAL OF CANCER 2022. 166: 229-239. Nº de citas: 12

[doi:10.1016/j.ejca.2022.02.017]
Torrús-Tendero D, Ramos-Rincón JM, Salvador F, Oliveira I, Llenas-García J, Arsuaga M, Crespillo-Andújar C, Pérez-Molina JA.

Imported fascioliasis in Spain: Report of 12 cases from the +REDIVI collaborative network (2009-2019).

TRAVEL MEDICINE AND INFECTIOUS DISEASE 2022. 47: 102286-102286.

[doi:10.1016/j.tmaid.2022.102286]
L?pez-Vélez R, Lebens M, Bundy L, Barriga J, Steffen R.

Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years.

TRAVEL MEDICINE AND INFECTIOUS DISEASE 2022. 47: 102293-102293. Nº de citas: 5

[doi:10.1016/j.tmaid.2022.102293]
Castón JJ, Cano A, Pérez-Camacho I, Aguado JM, Carratalá J, Ramasco F, Soriano A, Pintado V, Castelo-Corral L, Sousa A, Fariñas MC, Muñoz P, Abril López De Medrano V, Sanz-Peláez Ó, Los-Arcos I, Gracia-Ahufinger I, Pérez-Nadales E, Vidal E, Doblas A, Natera C, Martínez-Martínez L, Torre-Cisneros J.

Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 2022. 77(5): 1452-1460. Nº de citas: 21

[doi:10.1093/jac/dkac049]
Fortún J.

Diagnostic and therapeutic approach to fungal pneumonia in the critically ill patient.

REVISTA ESPANOLA DE QUIMIOTERAPIA 2022. 35 Suppl 1: 97-103. Nº de citas: 2

[doi:10.37201/req/s01.21.2022]
Domínguez-Domínguez L, Rava M, Bisbal O, Lopez-Cortés L, Portilla J, Podzamczer D, Olalla J, Fuster D, Rubio R, Jarrín I, Iribarren JA, Moreno S.

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018.

BMC INFECTIOUS DISEASES 2022. 22(1): 379-379.

[doi:10.1186/s12879-022-07352-z]
Bouza E, Arribas JR, Alejos B, Bernardino JI, Coiras M, Coll P, Del Romero J, Fuster MJ, Górgolas M, Gutiérrez A, Gracia D, Hernando V, Martínez-Picado J, Martínez Sesmero JM, Martínez E, Moreno S, Mothe B, Navarro ML, Podzamczer D, Pulido F, Ramos JT, Ruiz-Mateos E, Suárez García I, Palomo E.

Past and future of HIV infection. A document based on expert opinion.

REVISTA ESPANOLA DE QUIMIOTERAPIA 2022. 35(2): 131-156.

[doi:10.37201/req/083.2021]
Martínez-Sanz J, Vivancos-Gallego MJ, Fernández-Felix BM, Muriel A, Pérez-Elías P, Uranga A, Romero B, Galán JC, Moreno S, Pérez-Elías MJ.

An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population.

Microbiology spectrum 2022. 10(2): . Nº de citas: 1

[doi:10.1128/spectrum.02286-21]
García-Botella A, García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, Bouza E.

Booster or additional vaccination doses in patients vaccinated against COVID-19.

REVISTA ESPANOLA DE QUIMIOTERAPIA 2022. 35(2): 105-114. Nº de citas: 6

[doi:10.37201/req/149.2021]
García-Lledó A, Gómez-Pavón J, González Del Castillo J, Hernández-Sampelayo T, Martín-Delgado MC, Martín Sánchez FJ, Martínez-Sellés M, Molero García JM, Moreno Guillén S, Rodríguez-Artalejo FJ, Ruiz-Galiana J, Cantón R, De Lucas Ramos P, García-Botella A, Bouza E.

Pharmacological treatment of COVID-19: an opinion paper.

REVISTA ESPANOLA DE QUIMIOTERAPIA 2022. 35(2): 115-130. Nº de citas: 30

[doi:10.37201/req/158.2021]
Varona JF, Landete P, Lopez-Martin JA, Estrada V, Paredes R, Guisado-Vasco P, Fernandez de Orueta L, Torralba M, Fortun J, Vates R, Barberan J, Clotet B, Ancochea J, Carnevali D, Cabello N, Porras L, Gijon P, Monereo A, Abad D, Zuñiga S, Sola I, Rodon J, Vergara-Alert J, Izquierdo-Useros N, Fudio S, Pontes MJ, de Rivas B, Giron de Velasco P, Nieto A, Gomez J, Aviles P, Lubomirov R, Belgrano A, Sopesen B, White KM, Rosales R, Yildiz S, Reuschl AK, Thorne LG, Jolly C, Towers GJ, Zuliani-Alvarez L, Bouhaddou M, Obernier K, McGovern BL, Rodriguez ML, Enjuanes L, Fernandez-Sousa JM, Krogan NJ, Jimeno JM, Garcia-Sastre A.

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Life Science Alliance 2022. 5(4): . Nº de citas: 8

[doi:10.26508/lsa.202101200]
Martínez-Sanz J, Ron R, Moreno E, Sánchez-Conde M, Muriel A, López Cortés LF, Blanco JR, Pineda JA, Mena Á, Calzado Isbert S, Moreno S, Serrano-Villar S.

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.

Frontiers in immunology 2022. 13: 873408-873408. Nº de citas: 2

[doi:10.3389/fimmu.2022.873408]

Instituto Ramón y Cajal de investigación sanitaria

Unidades centrales de apoyo

Otros servicios científico-técnicos

Enfermedades Infecciosas

Buscador de publicaciones

Differences in saliva ACE2 activity among infected and non-infected adult and pediatric population exposed to SARS-CoV-2.

Fidaxomicin monotherapy versus standard therapy combined with bezlotoxumab for treating patients with Clostridioides difficile infection at high risk of recurrence: a matched cohort study

Response to Commentary: Long-term Changes of Inflammatory Biomarkers in Individuals on Suppressive Three-Drug or Two-Drug Antiretroviral Regimens.

Predictive value of CD8+ T cell and CD4/CD8 ratio at two years of successful ART in the risk of AIDS and non-AIDS events.

Risk of SARS-CoV-2 Reinfections in a Prospective Inception Cohort Study: Impact of COVID-19 Vaccination

Use of benznidazole to treat chronic Chagas disease: An updated systematic review with a meta-analysis.

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

Imported fascioliasis in Spain: Report of 12 cases from the +REDIVI collaborative network (2009-2019).

Bacterial travellers' diarrhoea: A narrative review of literature published over the past 10 years.

Impact of ceftazidime/avibactam versus best available therapy on mortality from infections caused by carbapenemase-producing Enterobacterales (CAVICOR study)

Diagnostic and therapeutic approach to fungal pneumonia in the critically ill patient.

Low CD4/CD8 ratio is associated with increased morbidity and mortality in late and non-late presenters: results from a multicentre cohort study, 2004-2018.

Past and future of HIV infection. A document based on expert opinion.

An Easy-to-Implement Risk Score for Targeted Hepatitis C Virus Testing in the General Population.

Booster or additional vaccination doses in patients vaccinated against COVID-19.

Pharmacological treatment of COVID-19: an opinion paper.

Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19.

Similar CD4/CD8 Ratio Recovery After Initiation of Dolutegravir Plus Lamivudine Versus Dolutegravir or Bictegravir-Based Three-Drug Regimens in Naive Adults With HIV.